The prognostic nutritional index (PNI) is commonly used to determine the nutritional and immune status of patients with cancer by calculating their serum albumin concentration and peripheral blood lymphocyte count. It is also used as a prognostic factor in patients with malignant tumors and those with many forms of cancer, but PNI has been poorly studied in prostate cancer. ...
mHSPC
Advertisement
Latest News
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Researchers studied several trials including LATITUDE and STAMPEDE to find similar characteristics among ARAT treatments.
The STAMPEDE trial examined the addition of zoledronic acid, docetaxel, or both to ADT for the treatment of mHSPC.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
The retrospective analysis evaluated the data of patients who underwent multiagent chemotherapy.
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm.
The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen.
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.